Aratana Therapeutics Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 17

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $238M

  • Investors
  • 1

Aratana Therapeutics General Information

Description

Developer of biopharmaceutical technology designed for companion animals. The company's portfolio consists of therapeutic candidates such as small-molecule pharmaceuticals and large-molecule biologics and consists of licensing proprietary technology from human biopharmaceutical companies or academia to develop therapeutics specifically for use in pets.

Contact Information

Website
www.aratana.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 11400 Tomahawk Creek Parkway
  • Suite 340
  • Leawood, KS 66211
  • United States
+1 (913)
Primary Industry
Other Commercial Products
Other Industries
Other Commercial Services
Acquirer
Elanco Animal Health
Corporate Office
  • 11400 Tomahawk Creek Parkway
  • Suite 340
  • Leawood, KS 66211
  • United States
+1 (913)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aratana Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Merger/Acquisition 18-Jul-2019 $238M Completed Generating Revenue
11. Secondary Transaction - Open Market 28-Apr-2016 Completed Generating Revenue
10. Secondary Transaction - Open Market 29-Apr-2014 Completed Generating Revenue
9. Secondary Transaction - Stock Distribution 03-Mar-2014 Completed Generating Revenue
8. 2PO 31-Jan-2014 Completed Generating Revenue
7. IPO 27-Jun-2013 Completed Generating Revenue
6. Debt - General 07-Mar-2013 Completed Generating Revenue
5. Later Stage VC (Series C) 31-Jan-2013 Completed Generating Revenue
4. Early Stage VC (Series B) 06-Dec-2011 $15.5M $35.5M Completed Product Development
3. Early Stage VC (Series A1) 07-Jan-2011 $10M $20M Completed Product Development
To view Aratana Therapeutics’s complete valuation and funding history, request access »

Aratana Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A1 2,750,000 $0.001000 8% $2 $2 1x $2 10.99%
Series A 10,000,000 $0.001000 8% $1 $1 1x $1 39.97%
To view Aratana Therapeutics’s complete cap table history, request access »

Aratana Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biopharmaceutical technology designed for companion animals. The company's portfolio consists of therapeuti
Other Commercial Products
Leawood, KS
17 As of 2023

Portland, ME
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aratana Therapeutics Competitors (1)

One of Aratana Therapeutics’s competitors is Immucell, a Corporation company based in Portland, ME.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immucell Corporation Portland, ME
You’re viewing 1 of 1 competitors. Get the full list »

Aratana Therapeutics Patents

Aratana Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2016211520-A1 Compositions and methods for chronic use of a weight-gaining compound Active 28-Jan-2015
AU-2016211520-B2 Compositions and methods for chronic use of a weight-gaining compound Active 28-Jan-2015
CA-2974012-A1 Compositions and methods for chronic use of a weight-gaining compound Active 28-Jan-2015
CA-2974012-C Compositions and methods for chronic use of a weight-gaining compound Active 28-Jan-2015
US-10064909-B2 Compositions and methods for chronic use of a weight-gaining compound Active 28-Jan-2015 A61K38/05
To view Aratana Therapeutics’s complete patent history, request access »

Aratana Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aratana Therapeutics Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Avalon Ventures Venture Capital Minority
Ewing Marion Kauffman Foundation Limited Partner Minority
Grassmere Partners PE/Buyout Minority
Kansas Bioscience Authority Government Minority
MPM BioImpact Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Aratana Therapeutics Investments & Acquisitions (3)

Aratana Therapeutics’s most recent deal was a Early Stage VC with ViroVet for . The deal was made on 09-Oct-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ViroVet 09-Oct-2017 Early Stage VC Other Agriculture
Okapi Sciences 06-Jan-2014 Merger/Acquisition Drug Delivery
Vet Therapeutics 16-Oct-2013 Merger/Acquisition Other Commercial Services
To view Aratana Therapeutics’s complete investments and acquisitions history, request access »

Aratana Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

30.35 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Aratana Therapeutics’s complete esg history, request access »

Aratana Therapeutics FAQs

  • When was Aratana Therapeutics founded?

    Aratana Therapeutics was founded in 2010.

  • Where is Aratana Therapeutics headquartered?

    Aratana Therapeutics is headquartered in Leawood, KS.

  • What is the size of Aratana Therapeutics?

    Aratana Therapeutics has 17 total employees.

  • What industry is Aratana Therapeutics in?

    Aratana Therapeutics’s primary industry is Other Commercial Products.

  • Is Aratana Therapeutics a private or public company?

    Aratana Therapeutics is a Private company.

  • What is the current valuation of Aratana Therapeutics?

    The current valuation of Aratana Therapeutics is .

  • What is Aratana Therapeutics’s current revenue?

    The current revenue for Aratana Therapeutics is .

  • How much funding has Aratana Therapeutics raised over time?

    Aratana Therapeutics has raised $179M.

  • Who are Aratana Therapeutics’s investors?

    Avalon Ventures, Ewing Marion Kauffman Foundation, Grassmere Partners, Kansas Bioscience Authority, and MPM BioImpact are 5 of 11 investors who have invested in Aratana Therapeutics.

  • Who are Aratana Therapeutics’s competitors?

    Immucell is a competitor of Aratana Therapeutics.

  • When was Aratana Therapeutics acquired?

    Aratana Therapeutics was acquired on 18-Jul-2019.

  • Who acquired Aratana Therapeutics?

    Aratana Therapeutics was acquired by Elanco Animal Health.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process